Alector, Inc. (ALEC, Financial) experienced a significant stock movement, dropping 5.21% to $1.82 per share. The trading volume reached 324,402 shares with a turnover rate of 0.33% and a price fluctuation of 5.78%. Recent financial data showed revenue of $15.34 million and a net loss of $42.22 million, resulting in an earnings per share of -$0.43 and a gross profit of $13.15 million. The price-to-earnings ratio stands at -1.07.
Analyst ratings reveal that out of 10 institutions, 60% recommend buying, 20% suggest holding, and 20% advise selling. The biotechnology sector, where Alector operates, saw a slight increase of 0.03%. Other active stocks in this sector include Clearmind Medicine Inc. and 180 Life Sciences Corp., with significant turnover rates and price fluctuations.
Alector is a clinical-stage biopharmaceutical company focused on developing therapies to treat neurodegeneration by restoring immune function in the brain. Its product pipeline includes AL001, AL002, AL003, and AL101.
